OR WAIT 15 SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
CDMOs adopt flexible processes for manufacturing investigational drug products.
Outsourcing companies fill the gap in drug development and manufacturing.
Liquid and lyophilized forms and preparing for the large capacity present challenges.
March 01, 2021
Accelerated drug development timelines must accommodate all crucial elements of nonclinical safety studies.
The acquisition strategically expands SPT Labtech’s offering in sample management for life sciences.
February 22, 2021
The second phase of the Myford facility expansion in California will add upstream and downstream processing suites.
February 17, 2021
The companies have expanded their existing partnership to include 40 Million Doses of COVID-19 vaccine for South Korea.
The acquisition will integrate drug substance, drug product, and clinical testing capabilities under Quotient.
February 04, 2021
The CGMP manufacturing agreement will expand production of lenzilumab, a candidate for COVID-19 therapy, to support a potential emergency use authorization filing.
PathoQuest will apply its experience in viral safety testing and quality control of biologics for mitigating the risk of adventitious agent contamination in biopharmaceutical manufacturing.
February 01, 2021
CDMOs address the unique challenges of liquid and lyophilized forms as well as preparing for the large capacity needed for COVID-19 vaccines.
January 28, 2021
Nexelis’ recent acquisition of GSK’s Marburg, Germany-based vaccines clinical bioanalytical laboratory expands its bioanalytical capabilities.
The £500,000 (US$686,294)-investment in mass spectrometry support will accelerate biologics development and approval.